Edinburgh, Scotland, 1 December 2021 – Green Bioactives Ltd (‘GBL’), a company pioneering the discovery, development and sustainable production of high-value plant natural products, announces it has appointed experienced agbio leader David McElroy, PhD as Non-executive Director.
Dr McElroy was previously a co-founder of agbio start-ups Verdia and NovaSynthetix, as well as natural gas-to-feed company Calysta. He was also instrumental in helping launch computation-based protein design company Arzeda and has held roles as President of agbiotech SME Targeted Growth at DuPont Food & Ag., VP of Business Development at Maxygen and Senior Scientist at DeKalb Genetics/Monsanto.
Dr McElroy obtained a PhD in Plant Molecular Biology from Cornell University where he was a Fulbright Scholar and NATO Overseas Fellow, as well as a BSc (Hons) in Plant Science from University of Aberdeen. David is an inventor on 17 patent families.
Professor Gary Loake, Chairman and CEO of Green Bioactives, said:
“I am very pleased to welcome David onto our Board. He has had a very successful executive career across many biotech sectors and has extensive experience leading cutting edge start-up organisations, including multiple leading agbio companies. David will further strengthen the Board with his deep knowledge in the areas of strategy, operation and fundraising as well as his expertise in plant science."
About Green Bioactives
Green Bioactives ("GBL”) is a world leader in the commercial utilisation of plant vascular stem cells, which has allowed it to create a reliable and economically attractive platform for the sustainable biomanufacturing of plant biomolecules for the cosmetics, pharma, food and agricultural industries.
GBL’s platform provides much improved and sustainable access to the huge, diverse, and valuable library of bioactives generated by the world’s plant population.
GBL is working with several world leading partners to produce high value bioactives that cannot be produced sustainably or economically using other approaches. The company’s capabilities span initial isolation of the bioactive producing plant cells through to the supply of the final purified product.
GBL’s knowledge of plant vascular stem cells also provides the opportunity for the company to develop novel approaches that address the global need for sustainable, more efficient food production.
GBL was founded in 2020 and is currently based at the Roslin Innovation Centre, Edinburgh, Scotland.
